
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRAZOLE | Bausch Health Companies | N-018859 DISCN | 1985-12-31 | 1 products, RLD |
| REBETOL | Merck & Co | N-020903 DISCN | 1998-06-03 | 2 products |
| COPEGUS | Roche | N-021511 DISCN | 2002-12-03 | 2 products, RLD |
| REBETOL | Merck & Co | N-021546 DISCN | 2003-07-29 | 1 products, RLD |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 68 | 282 | 257 | 169 | 184 | 906 |
| Hepatitis | D006505 | — | K75.9 | 50 | 203 | 184 | 131 | 155 | 687 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 33 | 179 | 183 | 108 | 139 | 614 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 37 | 162 | 146 | 120 | 136 | 577 |
| Chronic hepatitis | D006521 | — | K73.9 | 17 | 60 | 58 | 36 | 47 | 206 |
| Infections | D007239 | EFO_0000544 | — | 4 | 36 | 31 | 8 | 10 | 87 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 11 | 25 | 15 | 19 | 11 | 76 |
| Hepacivirus | D016174 | — | — | 4 | 22 | 18 | 7 | 9 | 54 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 4 | 23 | 23 | 4 | 3 | 50 |
| Communicable diseases | D003141 | — | — | 2 | 22 | 16 | 3 | 4 | 45 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 2 | 6 | 3 | — | 5 | 14 |
| Fever | D005334 | — | R50.9 | — | 7 | 1 | — | 4 | 12 |
| Viral hemorrhagic fevers | D006482 | — | A99 | — | 8 | 2 | — | 1 | 10 |
| Lassa fever | D007835 | EFO_0007338 | A96.2 | — | 5 | 1 | — | 3 | 8 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 5 | 1 | — | — | 6 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 2 | 2 | — | 2 | 5 |
| Botulism | D001906 | EFO_0005542 | A05.1 | — | 4 | 1 | — | — | 5 |
| Viral hepatitis human | D006525 | EFO_0004196 | — | 1 | 2 | 1 | — | 1 | 5 |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | 2 | 1 | — | 1 | 4 |
| Enterovirus infections | D004769 | EFO_0007255 | B34.1 | — | 2 | 1 | — | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | 1 | — | — | 1 | 8 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 5 | — | — | — | 5 |
| Leukemia | D007938 | — | C95 | 2 | 5 | — | — | — | 5 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 2 | — | — | 1 | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | 2 | 3 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | 3 | — | — | — | 3 |
| Syndrome | D013577 | — | — | — | 2 | — | — | 1 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | — | — | 1 | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | 1 | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | 1 | 2 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | 2 | — | — | — | — | 2 |
| Squamous cell neoplasms | D018307 | — | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 2 | 2 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 2 | 2 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 2 | 2 |
| Persistent infection | D000088562 | — | — | — | — | — | — | 2 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | — | E26 | — | — | — | — | 1 | 1 |
| Drug common name | Ribavirin |
| INN | ribavirin |
| Description | Ribavirin is a white powder and exists in two polymorphic forms. Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide. Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication. |
| Classification | Small molecule |
| Drug class | antivirals |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1 |
| PDB | — |
| CAS-ID | 36791-04-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1643 |
| ChEBI ID | 63580 |
| PubChem CID | 37542 |
| DrugBank | DB00811 |
| UNII ID | 49717AWG6K (ChemIDplus, GSRS) |






